Healthcare Providers and Services
Company Overview of Enzo Clinical Labs, Inc.
Enzo Clinical Labs, Inc. operates clinical reference laboratories in the United States. It offers various assays in the areas of chemistry, fertility and hormone studies, pregnancy, hematology, and coagulation. The company also provides electronic report delivery services for physicians. In addition, it offers phlebotomy services for patients needing blood tests through its network of patient service centers; diagnostic test that assists in risk assessment and early detection of lung cancer; and ColonSentry, a blood test to assess an individual's current risk for colorectal cancer. Enzo Clinical Labs, Inc. is based in Farmingdale, New York. The company has patient service centers in Manhatta...
60 Executive Boulevard
Farmingdale, NY 11735
Key Executives for Enzo Clinical Labs, Inc.
Chairman of the Board and Chief Executive Officer
President of Enzo Biochem Inc
Scientific Director and Associate Medical Director
Compensation as of Fiscal Year 2015.
Enzo Clinical Labs, Inc. Key Developments
Enzo Clinical Labs Announces Unaudited Earnings Results for the Third Quarter Ended April 30, 2015
Jun 9 15
Enzo Clinical Labs announced unaudited earnings results for the third quarter ended April 30, 2015. For the quarter, the company revenues grew to $15.7 million, an 8% increase over the prior year period. Operating income was $0.3 million, a $3.6 million turnaround from a year ago.
Enzo Clinical Labs, Inc. Reports Unaudited Earnings Results for the First Quarter Ended October 31, 2014
Dec 9 14
Enzo Clinical Labs, Inc. reported unaudited earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported that its results benefited from several factors, including greater emphasis and use of molecular diagnostic testing and increased operating efficiencies from streamlining efforts and recently implemented process and operational enhancements. Revenues increased 6%, to a record $15.8 million. Operating income was essentially breakeven, a $900,000 improvement compared to a year ago operating loss of approximately $0.9 million, and EBITDA was a positive $0.4 million, compared to last year’s negative EBITDA of $0.5 million.
Enzo Clinical Labs and Nuclea Biotechnologies Join to Market New Test for Certain High Risk Breast Cancer Patients
Feb 18 14
Enzo Biochem Inc. announced that its Enzo Clinical Labs subsidiary and Nuclea Biotechnologies, Inc. have entered into a non-exclusive distribution agreement to market Nuclea's non-invasive HER-2/neu serum test, a key assay in the monitoring of metastatic breast cancer. This blood test facilitates the monitoring and treatment decisions of women with metastatic breast cancer that over expresses the HER-2/neu protein in the tumor. Individuals with this condition tend to have a worse prognosis and a more aggressive disease that can resist certain types of chemotherapy. The test measures the portion of HER-2/neu protein that lies outside the surface of the cell and being released into the blood stream, allowing for more informed treatment decisions for a number of women who may not be responding to breast cancer treatment or may be at risk for metastatic cancer and need revised treatment plans. Utilizing the HER-2/neu blood test while monitoring the disease's progression will enable physicians to better adapt, combine therapies and change treatment protocols. Studies have demonstrated that use of combination chemotherapy regimens provides a statistically significant advantage for survival and tumor response in women with metastatic breast cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|